JP2024506291A - 吸入用のフューリンインヒビターの製剤 - Google Patents

吸入用のフューリンインヒビターの製剤 Download PDF

Info

Publication number
JP2024506291A
JP2024506291A JP2023547188A JP2023547188A JP2024506291A JP 2024506291 A JP2024506291 A JP 2024506291A JP 2023547188 A JP2023547188 A JP 2023547188A JP 2023547188 A JP2023547188 A JP 2023547188A JP 2024506291 A JP2024506291 A JP 2024506291A
Authority
JP
Japan
Prior art keywords
free form
pharmaceutical composition
compound
certain embodiments
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023547188A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506291A5 (enExample
Inventor
ツウェイ，シェン
ミシュラ，デニシュ，シャンデオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BP Asset V Inc
Original Assignee
BP Asset V Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BP Asset V Inc filed Critical BP Asset V Inc
Publication of JP2024506291A publication Critical patent/JP2024506291A/ja
Publication of JP2024506291A5 publication Critical patent/JP2024506291A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023547188A 2021-02-03 2022-02-03 吸入用のフューリンインヒビターの製剤 Pending JP2024506291A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163145363P 2021-02-03 2021-02-03
US63/145,363 2021-02-03
PCT/US2022/015098 WO2022169962A1 (en) 2021-02-03 2022-02-03 Formulation of furin inhibitor for inhalation

Publications (2)

Publication Number Publication Date
JP2024506291A true JP2024506291A (ja) 2024-02-13
JP2024506291A5 JP2024506291A5 (enExample) 2025-02-06

Family

ID=80446118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547188A Pending JP2024506291A (ja) 2021-02-03 2022-02-03 吸入用のフューリンインヒビターの製剤

Country Status (9)

Country Link
US (1) US20240307374A1 (enExample)
EP (1) EP4288052A1 (enExample)
JP (1) JP2024506291A (enExample)
KR (1) KR20230142752A (enExample)
CN (1) CN117222410A (enExample)
AU (1) AU2022215580A1 (enExample)
CA (1) CA3205921A1 (enExample)
IL (1) IL304858A (enExample)
WO (1) WO2022169962A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102023126563A1 (de) * 2023-09-28 2025-04-03 Philipps-Universität Marburg, Körperschaft des öffentlichen Rechts Hemmstoffe der Proproteinkonvertase Furin, Verfahren zu deren Herstellung und Verwendung

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012518663A (ja) * 2009-02-26 2012-08-16 グラクソ グループ リミテッド ４−｛（１ｒ）−２−［（６−｛２−［（２，６−ジクロロベンジル）オキシ］エトキシ｝ヘキシル）アミノ］−１−ヒドロキシエチル｝−２−（ヒドロキシメチル）フェノールを含む医薬製剤
JP2015500268A (ja) * 2011-12-09 2015-01-05 ラボラトワール・エスエムベ・ソシエテ・アノニム アゾール誘導体の吸入用乾燥粉末製剤
JP2017505784A (ja) * 2014-02-14 2017-02-23 レスピバート・リミテツド 抗炎症化合物としての芳香族複素環化合物
WO2019215341A1 (en) * 2018-05-11 2019-11-14 Glaxosmithkline Intellectual Property Development Limited Furin inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ535425A (en) 2002-03-13 2008-05-30 Biogen Idec Inc Anti-alphavbeta6 antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012518663A (ja) * 2009-02-26 2012-08-16 グラクソ グループ リミテッド ４−｛（１ｒ）−２−［（６−｛２−［（２，６−ジクロロベンジル）オキシ］エトキシ｝ヘキシル）アミノ］−１−ヒドロキシエチル｝−２−（ヒドロキシメチル）フェノールを含む医薬製剤
JP2015500268A (ja) * 2011-12-09 2015-01-05 ラボラトワール・エスエムベ・ソシエテ・アノニム アゾール誘導体の吸入用乾燥粉末製剤
JP2017505784A (ja) * 2014-02-14 2017-02-23 レスピバート・リミテツド 抗炎症化合物としての芳香族複素環化合物
WO2019215341A1 (en) * 2018-05-11 2019-11-14 Glaxosmithkline Intellectual Property Development Limited Furin inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DOUGLAS, LISA E.J. ET AL.: ""Furin Inhibition as a Mechanism to Reduce Aberrant ENaC‐Mediated Sodium Transport and Rehydrate t", THE FASEB JOURNAL, vol. 33, no. 1, JPN6025042960, April 2019 (2019-04-01), ISSN: 0005712173 *

Also Published As

Publication number Publication date
CA3205921A1 (en) 2022-08-11
KR20230142752A (ko) 2023-10-11
EP4288052A1 (en) 2023-12-13
IL304858A (en) 2023-10-01
WO2022169962A1 (en) 2022-08-11
US20240307374A1 (en) 2024-09-19
AU2022215580A9 (en) 2024-05-09
CN117222410A (zh) 2023-12-12
AU2022215580A1 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
TWI800567B (zh) 包含血漿激肽釋放酶抑制劑之劑型
CN103201262B (zh) 自分泌运动因子抑制剂及其用途
JP5461405B2 (ja) 嚢胞性線維症膜コンダクタンス制御因子の調節因子
CN104039775B (zh) Atp‑结合盒转运蛋白的调节剂
EP3856164B1 (en) Morphic forms of complement factor d inhibitors
RU2707887C2 (ru) Производное дигидроиндолизинона
CA3069226A1 (en) Methods of treatment for cystic fibrosis
TW201221128A (en) Crystalline forms of a factor Xa inhibitor
CN102421742A (zh) 3-戊基苯乙酸的盐及其药物用途
BR112021014956A2 (pt) Composições e compostos terapêuticos
JP2024506291A (ja) 吸入用のフューリンインヒビターの製剤
CN101583614A (zh) 用于治疗呼吸道合胞体病毒感染的多环试剂
BR112021008462A2 (pt) compostos e composições terapêuticas
JP7078722B2 (ja) 血漿カリクレイン阻害剤を含む剤形
RU2799824C2 (ru) Ингибиторы фурина
RU2827865C2 (ru) Производные хинолина для применения при лечении воспалительных заболеваний
IL303227B2 (en) Combined pumped storage power plant - desalination plant on the beach (ocean), or river, or lake
BR112020010154B1 (pt) Forma de dosagem sólida oral, seus usos e seus métodos de preparação
KR20230121762A (ko) (5s)-사이클로프로필-5-[3-[(3s)-4-(3,5-디플루오로페닐)-3-메틸-피페라진-1-일]-3-옥소-프로필]이미다졸리딘-2,4-디온의 고체 형태
HK40025124B (zh) 注射用组合物
HK40035163A (en) Dosage forms comprising a plasma kallikrein inhibitor
HK40035163B (en) Dosage forms comprising a plasma kallikrein inhibitor
HK1143363A (en) Modulators of cystic fibrosis transmembrane conductance regulator
HK1143363B (en) Modulators of cystic fibrosis transmembrane conductance regulator
HK1201827B (en) Modulators of atp-binding cassette transporters

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250129

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251014

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251021

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260410